Welcome to our dedicated page for Alaunos Therapeutics SEC filings (Ticker: TCRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alaunos Therapeutics, Inc. (TCRT) SEC filings page on Stock Titan provides direct access to the companys regulatory disclosures, including current reports, registration statements and financing-related documents. These filings show how Alaunos describes its business as combining T-cell receptor (TCR) cell therapy for solid tumors with a preclinical-stage obesity and metabolic health drug development program centered on a small molecule candidate.
Through its Forms 8-K, Alaunos reports material events such as strategic reprioritization steps, capital raises, changes in executive leadership, governance matters and listing status. Recent 8-Ks detail a registered direct offering of common stock and pre-funded warrants under a shelf registration statement on Form S-3, a private offering of Series A-2 Convertible Preferred Stock with dividend, voting and conversion terms, and a settlement and release agreement with The University of Texas M.D. Anderson Cancer Center regarding unpaid invoices under a research and development agreement. Other 8-Ks describe Nasdaq notices of non-compliance and subsequent confirmation that the company regained compliance, as well as stockholder approvals of amendments to increase authorized common stock and adjust capital structure.
Alaunos Form S-1 registration statement outlines its identity as a preclinical-stage obesity and metabolic health drug development company, while also summarizing its history as a clinical-stage oncology-focused cell therapy company and the August 2023 decision to wind down its TCR-T Library Phase 1/2 trial. The S-1 also explains an equity purchase agreement and related warrant that allow the company, at its discretion, to sell common stock to an institutional investor up to a specified aggregate amount.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, such as financing structures, conversion prices, dividend rights, share authorization changes and listing compliance updates. Users can quickly scan material agreements, capital markets transactions and corporate actions, and then open the full EDGAR documents for detailed review. This page is a central resource for understanding how Alaunos presents its strategy, risks, and capital structure in official SEC documents.
Director Jaime Vieser of Alaunos Therapeutics (TCRT) reported the acquisition of derivative securities in a Form 4 filing. On June 24, 2025, Vieser purchased 250 shares of Series A-2 Convertible Preferred Stock at $4.49 per share.
Key transaction details:
- The preferred stock is convertible to 55,679.29 shares of common stock
- The securities are held in direct ownership
- The preferred stock is perpetual with no expiration date
- Transaction code 'P' indicates an open market purchase
This insider purchase by a director could signal confidence in the company's future prospects. The convertible preferred stock provides potential upside exposure to common stock while offering preferred stockholder benefits.
Insider Trading Activity Report for Alaunos Therapeutics (TCRT) reveals significant transactions by Director Robert W. Postma. On June 24, 2025, Postma acquired 600 shares of Series A-2 Convertible Preferred Stock at $4.49 per share through WaterMill Asset Management Corp, convertible to 133,630.29 common shares.
Key holdings and transactions include:
- Direct ownership of 29,083 common shares, including recent acquisition of 20,804 shares at $2.92
- Indirect ownership through WaterMill Asset Management Corp of 33,333 common shares
- 500 Series A-1 Preferred Stock (convertible to 181,159 common shares) at $2.76
- Employee Stock Option for 3,737 shares at $10.30, vesting monthly through 2025
Notable ownership restrictions include a 4.99% beneficial ownership limit on converted preferred shares. The filing indicates continued insider investment in the company with diversified security types.
Alaunos Therapeutics (Nasdaq:TCRT) filed an 8-K disclosing a registered direct offering that closed on June 24 2025. The company sold 338,725 common shares at $3.36 and 271,674 pre-funded warrants at $3.359, generating gross proceeds of roughly $2.1 million before fees. Proceeds are earmarked for general corporate purposes, including capital expenditures and working capital. The Securities Purchase Agreement (Ex. 10.1) contains customary covenants; a legal opinion (Ex. 5.1) and a press release (Ex. 99.1) are also included. No other material operational changes were reported.
Alaunos Therapeutics (Nasdaq:TCRT) filed an 8-K reporting a private placement of 850 shares of Series A-2 Convertible Preferred Stock at $1,000 each, raising $850,000.
- Preferred shares carry a 10% annual dividend, payable in additional Series A-2 stock.
- Convertible into common at a fixed $4.49 price, with standard anti-dilution adjustments.
- Holders vote with common stock on an as-converted 1:1 basis.
- 1,000 shares authorized via a new Certificate of Designation; issuance closed on June 24 2025.
- Securities were sold under Rule 506(b); they are unregistered and subject to resale restrictions.
Items 1.01, 3.02, 3.03 and 5.03 disclose the agreement, equity issuance and charter amendment, all of which modify existing shareholder rights.
FAQ
What is the current stock price of Alaunos Therapeutics (TCRT)?
What is the market cap of Alaunos Therapeutics (TCRT)?
